

Curriculum Vitae

* Within 3 pages

Name in Full	Won-Mook Choi
Country	Republic of Korea
Affiliation	Asan Medical Center, University of Ulsan College of Medicine
Email	dr.choi85@gmail.com

Educational Background

Mar 2004 – Feb 2010 Doctor of Medicine, Seoul National University College of Medicine
 Mar 2013 – Feb 2015 MS in Internal Medicine, Seoul National University College of Medicine
 Mar 2015 – Feb 2019 PhD in Medical Science and Engineering, KAIST

Professional Career

Mar 2010 – Feb 2011 Medical Internship, Seoul National University Hospital
 Mar 2011 – Feb 2015 Residency in Internal Medicine, Seoul National University Hospital
 Mar 2019 – Feb 2021 Clinical Fellow in Gastroenterology, Asan Medical Center
 Mar 2021 – Feb 2022 Clinical Assistant Professor, Asan Medical Center
 Mar 2022 – Present Assistant Professor, Asan Medical Center, University of Ulsan College of Medicine

Research Field

Chronic Hepatitis B
 Hepatocellular Carcinoma
 Liver Fibrosis

- Choi WM**, Yip TC, Kim WR, Yee LJ, Brooks-Rooney C, Curteis T, Clark LJ, Jafry Z, Chen CH, Chen CY, Huang YH, Jin YJ, Jun DW, Kim JW, Park NH, Peng CY, Shin HP, Shin JW, Yang YH, Wong GL, Lim YS. Chronic Hepatitis B baseline viral load and on-treatment liver cancer risk: A multinational cohort study of HBeAg-Positive patients. *Hepatology*. 2024 Jan 24. doi: 10.1097/HEP.0000000000000752.
- Choi WM**, Kim GA, Choi J, Choi GH, Lee YB, Sinn DH, Lim YS. Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B. *Gut*. 2024 Mar 7;73(4):649-658.
- Jeon D, Cha HR, Chung SW, Choi J, Lee D, Shim JH, Kim KM, Lim YS, Lee HC, Lee SW, **Choi WM (co-corresponding)**. Association between statin use and the prognosis of hepatocellular carcinoma after resection: a nationwide cohort study. *EClinicalMedicine*. 2023 Nov 1:65:102300.
- Choi WM**, Yip TC, Wong GL, Kim WR, Yee LJ, Brooks-Rooney C, Curteis T, Cant H, Chen CH, Chen CY, Huang YH, Jin YJ, Jun DW, Kim JW, Park NH, Peng CY, Shin HP, Shin JW, Yang YH, Lim YS. Hepatocellular

carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis. *J Hepatol.* 2023 Mar;78(3):534-542.

5. **Choi WM**, Kim GA, Choi J, Han S, Lim YS. Increasing on-treatment hepatocellular carcinoma risk with decreasing baseline viral load in HBeAg-positive chronic hepatitis B. *J Clin Invest.* 2022 May 16;132(10):e154833.

6. **Choi WM**, Ryu T, Lee JH, Shim YR, Kim MH, Kim HH, Kim YE, Yang K, Kim K, Choi SE, Kim W, Kim SH, Eun HS, Jeong WI. Metabotropic glutamate receptor 5 in natural killer cells attenuates liver fibrosis by exerting cytotoxicity to activated stellate cells. *Hepatology.* 2021 Oct;74(4):2170-2185.

7. **Choi WM**, Choi J, Lim YS. Effects of Tenofovir vs Entecavir on Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection: A Systematic Review and Meta-analysis. *Clin Gastroenterol Hepatol.* 2021 Feb;19(2):246-258.e9.

8. **Choi WM**, Kim HH, Kim MH, Cinar R, Yi HS, Eun HS, Kim SH, Choi YJ, Lee YS, Kim SY, Seo W, Lee JH, Shim YR, Kim YE, Yang K, Ryu T, Hwang JH, Lee CH, Choi HS, Gao B, Kim W, Kim SK, Kunos G, Jeong WI. Glutamate Signaling in Hepatic Stellate Cells Drives Alcoholic Steatosis. *Cell Metab.* 2019 Nov 5;30(5):877-889.e7.